Combinational Therapy in Triple Negative Breast Cancer

Dr. Manzoor Ahmad Mir holds a Master’s Degree in Zoology from HNBG Central University and completed his Ph.D. in Immunology at Jawaharlal Nehru University, New Delhi, and CSIR-Institute of Microbial Technology, Chandigarh. His research focuses on Cancer Biology, Combination Therapy in Breast Cancer, and Tuberculosis Immunology. Dr. Mir has published over 50 high-impact research papers and book chapters, earning multiple awards and royalties. He has authored more than 15 books with international publishers like Elsevier and Springer-Nature. Dr. Mir serves on the editorial boards of prestigious journals and has been an invited speaker at numerous scientific conferences. He is a member of several scientific organizations, including the American Association of Cancer Research and the Royal British Society. He has received the TARE Fellowship and the SRFP-2019 from Indian science academies. Dr. Mir teaches Cancer Biology and Immunology at the University of Kashmir, where he heads the Department of Bioresources.

1. TNBC: an aggressive subtype of breast cancer2. Novel Biomarkers and Genetics: Role and Perspective3. Current Therapeutics and Treatment: Significance and controversies4. Conventional Adjuvant Chemotherapy in combination with Surgery, Radiotherapy and other non-specific agents5. Role of Immune system in Oncometastasis: A New Perspective6. What if immunotherapy is used in combination with the chemotherapy?7. Will there be any improvement if chemotherapy is combined with target specific biological agents?8. Different drug delivery Approaches in combinational Therapy